Statement of Deviation & Variation Report - March 31, 2026
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medicamen Biotech Ltd has filed its quarterly and annual statement confirming no deviation or variation in the utilization of funds raised through a preferential issue. The company had raised Rs. 53.57 crore (approximately) on April 24, 2025, and utilized Rs. 29.30 crore (approximately) by March 31, 2026, leaving about Rs. 24.27 crore still to be deployed. The funds were allocated towards drug development of 50 SKUs for regulated markets, registration of dossiers, enhanced working capital requirements, capital expenditure for facility upgrades, domestic market expansion, and general corporate purposes. The Audit Committee reviewed the utilization on May 27, 2026, and confirmed there is no deviation in fund usage.
This filing is neutral for investors as it confirms proper utilization of raised capital with no deviations reported. The company still has about 45% of the raised funds pending deployment, which should support future growth initiatives outlined in the objects of the issue.